行情

NVUS

NVUS

Novus
NASDAQ

实时行情|Nasdaq Last Sale

0.5200
-0.0120
-2.26%
盘后: 0.5200 0 0.00% 17:01 12/13 EST
开盘
0.5100
昨收
0.5320
最高
0.5850
最低
0.5003
成交量
12.12万
成交额
--
52周最高
5.21
52周最低
0.4000
市值
674.70万
市盈率(TTM)
-0.3303
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NVUS 新闻

  • 气候变化将对人类重要野生蔬菜构成灭绝威胁
  • 新浪财经综合.2小时前
  • 专家警告日本“绝种”风险!韩国问题更严重
  • 新浪财经综合.3小时前
  • 美政府调查第12起涉及特斯拉Autopilot交通事故
  • 新浪科技.3小时前
  • 英首相:回报选民信任的最好方式是尽快完成“脱欧”
  • 央视.4小时前

更多

所属板块

制药
-0.74%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

NVUS 简况

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
展开

Webull提供Novus Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。